
Healome Therapeutics Secures £2 Million for Ocular Drug Matrix
Patients with ocular surface diseases often face a daunting regimen of 20 drops a day, a cycle that leads to low adherence and poor outcomes. Birmingham-based Healome Therapeutics aims to break this pattern with a new polymer matrix that stays on the eye longer, securing £2 million in seed funding to reach human trials.


























